2023
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
Shatsky R, Thomas A, Yau C, Chien A, Falkson C, Stringer-Reasor E, Omene C, Trivedi M, Boughey J, Sanford A, Arora M, Sanft T, Nanda R, Isaacs C, Brown T, Hylton N, DeMichele A, Yee D, Esserman L. Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL. Journal Of Clinical Oncology 2023, 41: lba612-lba612. DOI: 10.1200/jco.2023.41.17_suppl.lba612.Peer-Reviewed Original ResearchImmune related adverse eventsWeeks x 4High-risk breast cancerPD-1 inhibitorsPathologic complete responseOral paclitaxelPeripheral neuropathyControl armBreast cancerRates of neutropeniaEfficacy of immunotherapyPhase 2 trialRelated adverse eventsHigh-risk cancerBiomarker subtypesI-SPY2Neoadjuvant agentWeekly trastuzumabOral agentsPrimary endpointAdverse eventsComplete responseOral combinationCombination therapyPump inhibitors
2021
Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith H, Schwab R, Yau C, Stringer-Reasor E, Wei S, Chien A, Albain K, Kalinsky K, Wallace A, Elias A, Yee D, Clark A, Boughey J, Han H, Nanda R, Isaacs C, Mitri Z, Lang J, Thomas A, Sanft T, DeMichele A, Perlmutter J, Rugo H, Hylton N, Symmans W, Melisko M, van't Veer L, Wilson A, Asare S, Sanil A, Berry D, Esserman L. Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2021, 81: pd1-10-pd1-10. DOI: 10.1158/1538-7445.sabcs20-pd1-10.Peer-Reviewed Original ResearchStage II/III breast cancerWeekly x 4I-SPY 2 TRIALI-SPY 2PCR rateBreast cancerI-SPYPeripheral neuropathyHigh-risk stage II/III breast cancerTumor samplesRates of peripheral neuropathyControl armEvaluate novel agentsPathological complete responsePhase 2 trialTreatment of angiosarcomaModerate to high expressionSide effect profileTime of surgeryBayesian predictive probability of successBreast tumor samplesAntibody drug conjugatesHR-HER2Complete responseNeoadjuvant therapy
2020
Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu M, Robinson P, Yau C, Wallace A, Chien A, Stringer-Reasor E, Nanda R, Yee D, Albain K, Boughey J, Han H, Elias A, Kalinsky K, Clark A, Kemmer K, Isaacs C, Lang J, Lu J, Sanft T, DeMichele A, Hylton N, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Haugen P, Wilson A, Singhrao R, Asare S, Sanil A, Berry D, Esserman L. Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2020, 80: p3-09-02-p3-09-02. DOI: 10.1158/1538-7445.sabcs19-p3-09-02.Peer-Reviewed Original ResearchPathological complete responseHER2 negative breast cancerI-SPY 2 TRIALWeeks of paclitaxelNegative breast cancerNeoadjuvant therapyBreast cancerHR-/HER2High-risk stage II/III breast cancerImmune-related adverse eventsPathologic complete response rateRandomized phase 2 trialStage II/III breast cancerHormone-receptorI-SPYEvaluate novel agentsGrade 3 colitisGrade 3 pneumonitisGrade 3 transaminitisPhase 2 trialPhase 3 trialBayesian predictive probability of successNeoadjuvant trialsWeekly paclitaxelComplete response